These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. Liu Y; Huang H; Chen Z; Zong L; Xiang J J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636 [TBL] [Abstract][Full Text] [Related]
4. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
5. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity. Nakamura M; Iwahashi M; Nakamori M; Ueda K; Matsuura I; Noguchi K; Yamaue H Clin Cancer Res; 2002 Aug; 8(8):2742-9. PubMed ID: 12171908 [TBL] [Abstract][Full Text] [Related]
6. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017 [TBL] [Abstract][Full Text] [Related]
10. [An in vitro study of specific antitumor immunity induced by dendritic cells pulsed with tumor cell lysates from patients with hepatocellular carcinoma]. Gao J; Chen M; Peng ML; Ren H Zhonghua Gan Zang Bing Za Zhi; 2005 Mar; 13(3):198-201. PubMed ID: 15760555 [TBL] [Abstract][Full Text] [Related]
11. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination. Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730 [TBL] [Abstract][Full Text] [Related]
12. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639 [TBL] [Abstract][Full Text] [Related]
13. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs. Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753 [TBL] [Abstract][Full Text] [Related]
14. Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor. Shilyansky J; Jacobs P; Doffek K; Sugg SL J Pediatr Surg; 2007 Jan; 42(1):54-61; discussion 61. PubMed ID: 17208541 [TBL] [Abstract][Full Text] [Related]
15. Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine. Lee HJ; Choi NR; Vo MC; Hoang MD; Lee YK; Lee JJ Methods Mol Biol; 2014; 1139():17-26. PubMed ID: 24619666 [TBL] [Abstract][Full Text] [Related]
16. Enhanced protective immunity derived from dendritic cells with phagocytosis of CD40 ligand transgene-engineered apoptotic tumor cells via increased dendritic cell maturation. Parameswaran S; Khalil M; Ahmed KA; Sharma RK; Xiang J Tumori; 2015; 101(6):637-43. PubMed ID: 25983089 [TBL] [Abstract][Full Text] [Related]
17. CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy. Onaitis MW; Kalady MF; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK Surgery; 2003 Aug; 134(2):300-5. PubMed ID: 12947333 [TBL] [Abstract][Full Text] [Related]
18. Tumor cell lysates as immunogenic sources for cancer vaccine design. González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929 [TBL] [Abstract][Full Text] [Related]
19. Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine. Foley R; Tozer R; Wan Y Transfus Med Rev; 2001 Oct; 15(4):292-304. PubMed ID: 11668436 [TBL] [Abstract][Full Text] [Related]
20. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]